CD110 Polyclonal Antibody
Sizes: 50μL, 100μL
Catalogue Numbers: RA22914-50, RA22914-100
Citations, Manuals and MSDS Available upon request.
Background: MPL proto-oncogene, thrombopoietin receptor (MPL) Homo sapiens In 1990 an oncogene, v-mpl, was identified from the murine myeloproliferative leukemia virus that was capable of immortalizing bone marrow hematopoietic cells from different lineages. In 1992 the human homologue, named, c-mpl, was cloned. Sequence data revealed that c-mpl encoded a protein that was homologous with members of the hematopoietic receptor superfamily. Presence of anti-sense oligodeoxynucleotides of c-mpl inhibited megakaryocyte colony formation. The ligand for c-mpl, thrombopoietin, was cloned in 1994. Thrombopoietin was shown to be the major regulator of megakaryocytopoiesis and platelet formation. The protein encoded by the c-mpl gene, CD110, is a 635 amino acid transmembrane domain, with two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs . TPO-R deficient mice were severely thrombocytopenic, emphasizing the important
Condition: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Storage Instructions: -20°C/1 year
Recommended dilutions: Western Blot: 1/500 - 1/2000. IHC-p: 1/100-1/300. ELISA: 1/20000. Not yet tested in other applications.
Alternative Names: MPL; TPOR; Thrombopoietin receptor; TPO-R; Myeloproliferative leukemia protein; Proto-oncogene c-Mpl; CD110
Applications: WB; IHC-p; IF (paraffin section) ; ELISA
Species Cross-Reactivity: Human; Mouse; Rat
GeneID (Human): 4352
Protein MW (KDa): 69,40
SWISS: P40238
Source: Rabbit
Research Use Only